News|Articles|November 19, 2026

FDA Approves Livsayis, Regeneron's First siRNA Therapy for Myasthenia Gravis

Listen
0:00 / 0:00

Key Takeaways

  • FDA approval covers AChR-positive generalized myasthenia gravis in adults, introducing a subcutaneous siRNA regimen administered four times annually and expanding complement-directed options beyond frequent dosing paradigms.
  • NIMBLE, a randomized double-blind phase 3 trial across 86 sites, met its week-24 primary endpoint with MG-ADL improvement of 4.5 versus 2.2 for placebo (P=.0005).
SHOW MORE

Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.

The FDA has approved Livsayis (cemdisiran), a subcutaneous small interfering RNA (siRNA) therapy from Regeneron Pharmaceuticals, for adults with generalized myasthenia gravis who are anti-acetylcholine receptor (AChR) antibody-positive.1 The Nov. 18 decision gives the company its first approved siRNA therapy and its first neurology medicine, according to Regeneron.1

Regeneron describes Livsayis as the only FDA-approved myasthenia gravis treatment that is given subcutaneously four times a year.1 The agency reviewed the application on a priority timeline with a target action date in November 2026, after the company used a priority review voucher.2

Regeneron holds worldwide rights through a license agreement with Alnylam.1

“In the Phase 3 NIMBLE trial, Livsayis delivered rapid, deep disease control – maintained through the end of dosing intervals – and offers a four-times-a-year subcutaneous dosing schedule,” said Tuan Vu, M.D., professor of neurology at the University of South Florida Morsani College of Medicine and a global principal investigator of the trial.1

Key Facts

  • Drug: Livsayis (cemdisiran), C5-directed siRNA
  • Indication: AChR-positive generalized myasthenia gravis
  • Trial: Phase 3 NIMBLE, placebo-controlled
  • MG-ADL: 4.5-point gain vs 2.2 with placebo (wk 24)
  • QMG: 4.2-point gain vs 1.5 with placebo (wk 24)
  • Safety: Boxed Warning for meningococcal infection
  • Status: FDA approved; EU decision due 2H 2027

What did the NIMBLE trial show?

NIMBLE is a randomized, double-blind, placebo-controlled phase 3 study that Regeneron calls the largest interventional trial in the disease to date.1 Participants with AChR-positive disease received one of four subcutaneous regimens: Livsayis every three months; Livsayis plus a monoclonal antibody that inhibits complement component 5 (C5); the antibody alone; or placebo.1

The trial ran at 86 centers in 13 countries, and results were published in The Lancet in 2026.3 The primary endpoint was change from baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 24, a patient-reported scale from 0 to 24.1

The key secondary endpoint was change in the Quantitative Myasthenia Gravis (QMG) total score, a clinician-assessed measure scored from 0 to 39.1 At week 24, the MG-ADL score improved by 4.5 points with Livsayis and 2.2 points with placebo, a placebo-adjusted difference of 2.3 points (P=.0005).1

The QMG score improved by 4.2 points versus 1.5 points, a placebo-adjusted difference of 2.8 points (P=.0015).1 Responder analyses favored Livsayis: 76.6% of patients had an MG-ADL improvement of at least 3 points versus 44.1% with placebo, and 48.4% had a QMG improvement of at least 5 points versus 19.0%.1

Regeneron reports improvement as early as two weeks.1 The published analysis did not find added benefit from combining the antibody with cemdisiran compared with cemdisiran alone.3

What safety requirements come with Livsayis?

The prescribing information carries a Boxed Warning for serious meningococcal infections, along with warnings for other serious infections, particularly those caused by encapsulated bacteria such as Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria gonorrhoeae.1 Patients must complete meningococcal vaccination at least two weeks before the first dose, and those who must start sooner also need antibiotics.1

The drug is available only through a Risk Evaluation and Mitigation Strategy program, and patients carry a safety card during treatment and for 12 months after the last dose.1 The most common adverse reactions, occurring in at least 5% of treated patients and more often than with placebo, were injection site reactions, viral infections and urinary tract infections.1

Safety and efficacy in children have not been established.1

Why are more generalized myasthenia gravis treatment options so important?

The disease is rare, chronic and autoimmune, marked by unpredictable and potentially life-threatening muscle weakness.1 In its most common form, abnormal anti-AChR antibodies activate the complement system, including C5, disrupting communication between nerves and muscles.1

Regeneron cites about 85,000 patients in the United States.1 Vu said many patients still have suboptimal control because of waning therapeutic effect, inadequate response or high treatment burden.1

Samantha Masterson, president and CEO of the Myasthenia Gravis Foundation of America, said, “With Livsayis, those living with generalized myasthenia gravis have a new option that may help maintain disease control while reducing the burden treatment can place on daily life.”1

How does cemdisiran work, and what does it mean for Regeneron?

Livsayis degrades the messenger RNA that encodes C5, which blocks production of the protein, lowers circulating levels and inhibits terminal complement activation, a key driver of AChR-positive disease.1

“Livsayis is Regeneron’s first approved medicine in neurology, and an important new option for people living with generalized myasthenia gravis who need effective disease control without a heavy treatment burden,” said George D. Yancopoulos, M.D., Ph.D., board co-chair, president and chief scientific officer of Regeneron.1

What limitations and open questions remain?

The efficacy data rest on a 24-week primary endpoint, and NIMBLE is ongoing, so durability and long-term safety beyond that window are not established in the materials reviewed.1 The release reports no head-to-head comparison with other approved complement inhibitors, and pricing was not disclosed.

A European Union decision is expected in the second half of 2027, and submissions are planned in additional markets, including Japan.1

Sources

  1. Livsayis (cemdisiran) approved by the FDA as first and only siRNA therapy in generalized myasthenia gravis and only treatment with four-times-a-year subcutaneous dosing. News release. Regeneron Pharmaceuticals, Inc. November 18, 2026. Accessed November 19, 2026. https://investor.regeneron.com/news-releases/news-release-details/livsayistm-cemdisiran-approved-fda-first-and-only-sirna-therapy
  2. Cemdisiran regulatory submissions accepted for review by FDA and EMA for the treatment of generalized myasthenia gravis (gMG). News release. Regeneron Pharmaceuticals, Inc. June 22, 2026. Accessed November 19, 2026. https://www.drugs.com/nda/cemdisiran_260622.html
  3. Vu T, Habib AA, Jacob S, et al. Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;407(10540):1712-1725. doi:10.1016/S0140-6736(26)00690-2

Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.